

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

November 29, 2004

Date

Jessica Gaunt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Stephen D. Harrison et al.

Application No. : 10/733,816

Filed : December 10, 2003

For : GSK3 POLYPEPTIDES

Art Unit : 1645

Docket No. : 59516-36/PP-15876.009

Date : November 29, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT


Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 10/211,412, filed July 31, 2002. The references listed on the attached form PTO/SB/08 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office


in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application. No fee is due at this time in accordance with 37 C.F.R. § 1.97(b).

Respectfully submitted,
Stephen D. Harrison et al.
DAVIS WRIGHT TREMAINE LLP

By 
Jane E. R. Potter
Registration No. 33,332

2600 Century Square
1501 Fourth Avenue
Seattle, WA 98101-1688
Phone: (206) 628-7650
Facsimile: (206) 628-7699



PTO/SB/08A (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds of Documents of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/733,816		
		Filing Date	December 10, 2003		
		First Named Inventor	Stephen D. Harrison		
		Art Unit	1645		
		Examiner Name			
Sheet	2	of	3	Attorney Docket Number	59516-36/PP-15876.009

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SUMMERS ET AL., <i>The Role of Glycogen Synthase Kinase 3β in Insulin-Stimulated Glucose Metabolism</i> , JOURNAL OF BIOLOGICAL CHEMISTRY, 274(25):17934-17940, 1999.	
		Accession No. AAA84444.1, 1996.	
		Database EMBL Entry, Accession No. P49840, 1996.	
		Database EMBL Entry, Accession No. P49841, 1996.	
		Database EMBL Entry, Accession No. Q91627, 1996.	
		Database EMBL Entry, Accession No. U31862, 1995.	
		LATIMER ET AL., <i>Stimulation of MAP Kinase by V-Raf Transformation of Fibroblasts Fails to Induce Hyperphosphorylation of Transfected Tau</i> , FEBS LETTERS, 365(1):42-46, 1995.	
		CROSS ET AL., <i>The Inhibition of Glycogen Synthase Kinase-3 by Insulin or Insulin-Like Growth Factor 1 in the Rat Skeletal Muscle Cell Line L6 is Blocked by Wortmannin, but Not by Rapamycin: Evidence that Wortmannin Blocks Activation of the Mitogen-Activated Protein Kinase Pathway in L6 Cells Between Ras and Raf</i> , BIOCHEMICAL JOURNAL, 303(Part 1):21-26, 1994.	
		LOVESTONE ET AL., <i>Alzheimer's Disease-Like Phosphorylation of the Microtubule-Associated Protein Tau by Glycogen Synthase Kinase-3 in Transfected Mammalian Cells</i> , CURRENT BIOLOGY, 4(12):1077-1086, 1994.	
		MULOT ET AL., <i>PHF-Tau from Alzheimer's Brain Comprises Four Species on SDS-PAGE Which Can Be Mimicked by in Vitro Phosphorylation of Human Brain Tau by Glycogen Synthase Kinase-3β</i> , FEBS LETTERS, 349(3):359-364, 1994.	
		PEIFER ET AL., <i>Phosphorylation of the Drosophila Adherens Junction Protein Armadillo: Roles for Wingless Signals and Zeste-White 3 Kinase</i> , DEVELOPMENTAL BIOLOGY, 166(2):543-556, 1994.	
		SAITO ET AL., <i>The Mechanism by Which Epidermal Growth Factor Inhibits Glycogen Synthase Kinase 3 in A431 Cells</i> , BIOCHEMICAL JOURNAL, 303(Part 1):27-31, 1994.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/733,816
		Filing Date	December 10, 2003
		First Named Inventor	Stephen D. Harrison
		Art Unit	1645
		Examiner Name	
Sheet	3	of	3
		Attorney Docket Number	59516-36/PP-15876.009

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MANDELKOW ET AL., <i>Tau as a Marker for Alzheimer's Disease</i> , TIBS, 18(12):480-483, 1993.	
		VAN DER LINDEN ET AL., <i>Domain Organization of Penicillin-Binding Protein 5 from Escherichia Coli Analysed by C-Terminal Truncation</i> , BIOCHEMICAL JOURNAL, 289(Part 2):593-598, 1993.	
		WELSH ET AL., <i>Glycogen Synthase Kinase-3 is Rapidly Inactivated in Response to Insulin and Phosphorylates Eukaryotic Initiation Factor eIF-2B</i> , BIOCHEMICAL JOURNAL, 294(Part 3):625-629, 1993.	
		JANCARIK ET AL., <i>Sparse Matrix Sampling: A Screening Method for Crystallization of Proteins</i> , J. OF APPLIED CRYSTALLOGRAPHY, 24(4):409-411, 1991.	
		WOODGETT, <i>A Common Denominator Linking Glycogen Metabolism, Nuclear Oncogenes and Development</i> , TIBS, 16(5):177-181, 1991.	
		RANTY ET AL., <i>Truncation of Ribulose-1, 5-Bisphosphate Carboxylase/Oxygenase (Rubisco) from Holoenzyme Assembly and Activity</i> , EMBO JOURNAL, 9:1365-1373, 1990.	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.